PPARγ GENE AND ATHEROSCLEROSIS:
GENETIC POLYMORPHISMS, EPIGENETICS
AND THERAPEUTIC IMPLICATIONS Grbić E, Peterlin A, Kunej T, Petrovič D *Corresponding Author: Professor Daniel Petrovič, M.D., Ph.D., Institute of Histology and Embryology, Faculty of Medicine
University Ljubljana, Vrazov trg 2, Ljubljana 1000, Slovenia. Tel: +386-1-5437-360. Fax: +386-1-5437-361. E-mail:
Daniel.petrovic@mf.uni-lj.si page: 39
|
CONCLUSIONS
There are conflicting views on the role of PPARG
polymorphisms at the onset of atherosclerosis. The reason
may be the different genetic background of the observed
population. The current, meta-analyzes of the effects of PPAR polymorphism on the development of atherosclerosis
are heterogeneous with an unclear conclusion. We
believe it is important to perform meta-analysis only in
Caucasian or Asian populations, due to the impact of different
genetic or epigenetic factors, which would contribute to
a better understanding of the impact of these factors on the
onset and the development of atherosclerosis in different
populations. Some studies were done on a small number
of subjects, some had a low average life-span, therefore
larger and prospective studies with homogeneous groups
had to be carried out. It is also necessary to examine in
more detail the effect of polymorphisms investigated at the
onset of atherosclerosis and their role in T2DM patients.
Many studies have shown a significant effect of epigenetic
factors in the development and onset of atherosclerosis
but also other CVDs. However, the mechanism of origin
is not adequately described, which must be accurately determined.
Namely, epigenetic studies of atherosclerosis can
offer very good therapeutic solutions for CVDs and their
prevention. Due to the contrary attitudes about the effect
of TZDs therapy on the processes of atherosclerosis and
the occurrence of adverse effects in T2DM patients with
CVD, it is necessary to decisively investigate mechanisms
of action of PPARγ agonists in order to prevent the onset
and progression of atherosclerosis in T2DM patients.
Declaration of Interest. The authors report no conflicts
of interest. The authors alone are responsible for the
content and writing of this article.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|